The heterobivalent (SSTR2/albumin) radioligand [
Animals
Receptors, Somatostatin
/ metabolism
Mice
Copper Radioisotopes
Radiopharmaceuticals
/ pharmacokinetics
Heterocyclic Compounds, 1-Ring
Humans
Albumins
Cell Line, Tumor
Pheochromocytoma
/ radiotherapy
Acetates
/ chemistry
Theranostic Nanomedicine
/ methods
Tissue Distribution
Female
Disease Models, Animal
SPECT imaging
albumin binder
allograft model
copper-67
dosimetry
pheochromocytoma
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2024
2024
Historique:
received:
25
06
2024
accepted:
08
08
2024
medline:
23
9
2024
pubmed:
23
9
2024
entrez:
23
9
2024
Statut:
epublish
Résumé
Somatostatin type 2 receptor (SSTR2) radionuclide therapy using β
Identifiants
pubmed: 39310112
doi: 10.7150/thno.100091
pii: thnov14p5371
pmc: PMC11413788
doi:
Substances chimiques
Receptors, Somatostatin
0
Copper Radioisotopes
0
Radiopharmaceuticals
0
1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane
0
Heterocyclic Compounds, 1-Ring
0
Albumins
0
Acetates
0
Copper-67
0
Sstr2 protein, mouse
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5371-5387Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.